MONMOUTH JUNCTION, N.J., Nov. 13, 2006 (PRIMEZONE) -- MedaSorb Technologies Corporation (OTCBB:MSBT) announced today that it has filed a new patent application covering its Ultra Select(tm) polymer technology. This new technology extends MedaSorb’s line of products that are in the process of commercialization. The polymer is being developed for use with medical applications requiring long term use and extended treatment times, such as nightly dialysis. MedaSorb believes that its Ultra Select(tm) polymer is highly selective in extracting only midsize proteins, such as cytokines and B2-microglobulin, from blood and other physiologic fluids, while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact. This patent application, once approved, will further strengthen MedaSorb’s intellectual property portfolio.
